Concizumab

N/A

Report date: 2024/12/25 15:59:32
First In Class

Base Information

Drug NameConcizumab
Drug Alias NameAlhemoNNC-0172-2021NNC-172-2021mAbTFPI2021NN-7415 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTissue factor pathway inhibitor inhibitors
TargetsTissue factor pathway inhibitor
Therapy Area/IndicationsHemorrhageHemophilia BHemophilia A
Global Approved IndicationsHemophilia BHemophilia A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date2023/04/17
Country/TerritoryCzechiaBosnia and HerzegovinaBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk Pharma LtdNovo Nordisk Canada IncNovo Nordisk Inc +[4] 
Inactive CompaniesN/A
Active IndicationsHemophilia BHemophilia A
Inactive IndicationsHemorrhage

Other Information

ATC CodeN/A
Related LinksN/A